Drug recall · May 13, 2026
Duloxetine Delayed-Release Capsules USP recall
Why: CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90.
- Lots / codes
Lot: 241069C, Exp 05/31/2027
- Quantity
- 165,761 90-count bottles
- Company
- Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ
- Distribution
- Nationwide in the USA
- Initiated
- April 21, 2026 · Voluntary: Firm initiated
- Classified
- May 6, 2026
- Reported
- May 13, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.